UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery

The New England journal of medicine, 2012-02, Vol.366 (5), p.409-420

2012

Volltextzugriff (PDF)

Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids

The New England journal of medicine, 2012-02, Vol.366 (5), p.421-432

2012

Volltextzugriff (PDF)

Long-term treatment of uterine fibroids with ulipristal acetate

Fertility and sterility, 2014-06, Vol.101 (6), p.1565-1573.e18

2014

Volltextzugriff (PDF)

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

Fertility and sterility, 2015-02, Vol.103 (2), p.519-527.e3

2015

Volltextzugriff (PDF)

Long-term medical management of uterine fibroids with ulipristal acetate

Fertility and sterility, 2016, Vol.105 (1), p.165-173.e4

2016

Volltextzugriff (PDF)

Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration

Journal of clinical medicine, 2021-12, Vol.10 (24), p.5794

2021

Volltextzugriff (PDF)

The potential of selective progesterone receptor modulators for the treatment of uterine fibroids

Expert Review of Endocrinology & Metabolism, 2014-01, Vol.9 (1), p.79-92

2014

Volltextzugriff (PDF)

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Fertility and sterility, 2020-07, Vol.114 (1), p.44-55

2020

Volltextzugriff (PDF)

Incidence of Mood Disorders in Women Treated With Linzagolix: 52-week Results From Two Phase 3 Trials [A106]

Obstetrics and gynecology (New York. 1953), 2022-05, Vol.139 (1), p.31-31S

2022

Volltextzugriff (PDF)

Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]

Obstetrics and gynecology (New York. 1953), 2022-05, Vol.139 (1), p.30-30S

2022

Volltextzugriff (PDF)

Post-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]

Obstetrics and gynecology (New York. 1953), 2022-05, Vol.139 (1), p.31-32S

2022

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF LINZAGOLIX FOR THE TREATMENT OF SEVERE ADENOMYOSIS: FINAL Results FROM A PILOT STUDY

Fertility and sterility, 2021-09, Vol.116 (3), p.e327-e327

2021

Volltextzugriff (PDF)

ADMINISTRATION OF HORMONAL ADD-BACK THERAPY (ABT) COUNTERACTS THE UTERINE VOLUME REDUCING EFFECTS OF ORAL GnRH ANTAGONIST THERAPY

Fertility and sterility, 2021-09, Vol.116 (3), p.e316-e317

2021

Volltextzugriff (PDF)

Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study

Reproductive biomedicine online, 2022-01, Vol.44 (1), p.200-203

2022

Volltextzugriff (PDF)

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

The Lancet (British edition), 2022-09, Vol.400 (10356), p.896-907

2022

Volltextzugriff (PDF)

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)

Human reproduction (Oxford), 2024-06, Vol.39 (6), p.1208-1221

2024

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS

Fertility and sterility, 2020-09, Vol.114 (3), p.e527-e527

2020

Volltextzugriff (PDF)

Quality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain [30B]

Obstetrics and gynecology (New York. 1953), 2020-05, Vol.135 (1), p.26-27S

2020

Volltextzugriff (PDF)

Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment [25B]

Obstetrics and gynecology (New York. 1953), 2020-05, Vol.135 (1), p.25-25S

2020

Volltextzugriff (PDF)

Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age

Reproductive sciences (Thousand Oaks, Calif.), 2014-10, Vol.21 (10), p.1256-1265

2014

Volltextzugriff (PDF)

Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment

Fertility and sterility, 2019-09, Vol.112 (3), p.e323-e323

2019

Volltextzugriff (PDF)

The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]

Obstetrics and gynecology (New York. 1953), 2019-05, Vol.133 (1), p.112-113S

2019

Volltextzugriff (PDF)

Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials

Obstetrical & gynecological survey, 2022-12, Vol.77 (12), p.741-742

2022

Volltextzugriff (PDF)

Expulsion of a uterine myoma in a patient treated with ulipristal acetate

Clinical case reports, 2015-04, Vol.3 (4), p.240-242

2015

Volltextzugriff (PDF)

Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery

The New England journal of medicine, 2012, Vol.366 (5), p.409-420

2012

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(26)
Russisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery

Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids

Long-term treatment of uterine fibroids with ulipristal acetate

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

Long-term medical management of uterine fibroids with ulipristal acetate

Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration

The potential of selective progesterone receptor modulators for the treatment of uterine fibroids

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Incidence of Mood Disorders in Women Treated With Linzagolix: 52-week Results From Two Phase 3 Trials [A106]

Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]

Post-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]

EFFICACY AND SAFETY OF LINZAGOLIX FOR THE TREATMENT OF SEVERE ADENOMYOSIS: FINAL Results FROM A PILOT STUDY

ADMINISTRATION OF HORMONAL ADD-BACK THERAPY (ABT) COUNTERACTS THE UTERINE VOLUME REDUCING EFFECTS OF ORAL GnRH ANTAGONIST THERAPY

Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)

EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS

Quality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain [30B]

Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment [25B]

Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age

Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment

The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]

Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials

Expulsion of a uterine myoma in a patient treated with ulipristal acetate

Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery

Suchergebnisse filtern